← Back to Search

Retinoid

Delgocitinib Cream and Alitretinoin for Chronic Hand Dermatitis

Phase 3
Waitlist Available
Research Sponsored by LEO Pharma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 26 weeks
Awards & highlights
No Placebo-Only Group
Pivotal Trial

Summary

This trial tests two treatments for adults with severe chronic hand eczema who haven't improved with standard treatments. Participants will use either a special cream or take capsules to see which works better in reducing symptoms and improving quality of life.

Eligible Conditions
  • Eczema

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~26 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 26 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in HECSI score from baseline to Week 12
Secondary study objectives
AUC of HECSI-90 from baseline up to Week 24
AUC of change from baseline in DLQI score up to Week 24
Change in HECSI score from baseline to Week 24
+7 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Delgocitinib cream 20 mg/gExperimental Treatment1 Intervention
Twice-daily topical application for up to 24 weeks
Group II: Alitretinoin capsules 30 mg per capsuleActive Control1 Intervention
1 capsule per day for up to 24 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Delgocitinib
2021
Completed Phase 3
~1330

Find a Location

Who is running the clinical trial?

LEO PharmaLead Sponsor
271 Previous Clinical Trials
188,360 Total Patients Enrolled
45 Trials studying Eczema
19,739 Patients Enrolled for Eczema
Medical ExpertStudy DirectorLEO Pharma
55 Previous Clinical Trials
9,799 Total Patients Enrolled
21 Trials studying Eczema
4,689 Patients Enrolled for Eczema

Media Library

Alitretinoin Capsules (Retinoid) Clinical Trial Eligibility Overview. Trial Name: NCT05259722 — Phase 3
Alitretinoin Capsules (Retinoid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05259722 — Phase 3
~147 spots leftby Dec 2025